Premium
Single weekly doses of oral sulfamethoxypyridazine in preventing recurrences of rheumatic fever
Author(s) -
Feinstein Alvan R.,
Glazko Anthony J.,
Spagnuolo Mario
Publication year - 1966
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt196674501
Subject(s) - medicine , sulfadiazine , regimen , adverse effect , rheumatic fever , sulfonamide , anesthesia , antibiotics , chemistry , stereochemistry , microbiology and biotechnology , biology
A single weekly dose of sulfamethoxypyridazine (SMP), 3.0 Gm., provided rheumatic children and adolescents with higher blood levels of the drug through most of the week than peak values after single daily doses of sulfadiazine, 1.0 Gm. When tested in a program of prophylaxis against recurrences of rheumatic fever, the repetitive weekly dose of SMP was maintained continuously with about the same degree of fidelity given to a daily oral sulfadiazine regimen. The SMP regimen seemed more effective than daily sulfadiazine for preventing streptococcal infections but not for preventing rheumatic recurrences. Although no significant adverse effects of SMP were noted, the reports of severe reactions in other circumstances have discouraged further clinical trials with long‐acting sulfonamide preparations. When newer and safer long‐acting sulfonamides become available, their value in antirheumatic prophylaxis should be explored.